Psychiatry

814 questions

Question 1Question →

Match each clinical presentation of a patient with a depressive disorder to the most appropriate next step in clinical management.

Click a left item, then click its matching right item

Items

An 81-year-old male with severe depression who has refused all food and fluids for a week, resulting in hospitalization for acute renal failure and dehydration.
A 39-year-old female whose depressive symptoms remitted on fluoxetine, but who now requests a medication change due to persistent, distressing anorgasmia.
A 22-year-old university student prescribed citalopram for low mood three weeks ago, now brought to the emergency department for severe agitation, hyper-religiosity, and going without sleep for four days.
A 48-year-old female who reports a 40 percent reduction in depressive symptoms after eight weeks of maximum-dose escitalopram, but continues to struggle with severe residual anhedonia.

Matches

Show answer & explanation

Answer

The 81-year-old refusing food requires urgent electroconvulsive therapy. The 39-year-old with sexual dysfunction should cross-taper to bupropion. The 22-year-old with manic symptoms must have the antidepressant discontinued immediately. The 48-year-old with a partial response should be augmented with an atypical antipsychotic.
Each patient represents a critical decision point in the management of depressive disorders. Life-threatening physiological decline requires ECT, SSRI-induced sexual dysfunction is managed with bupropion, treatment-emergent mania requires stopping the antidepressant, and partial SSRI responders benefit from augmentation.

Step-by-Step Solution

1
Assess the severity and safety profile of the 81-year-old male.
The patient is at imminent risk of death from dehydration and acute renal failure.
Life-threatening emergencies in major depressive disorder (like severe suicidality or starvation) require the fastest acting treatment, which is electroconvulsive therapy (ECT).
2
Identify the primary medication adverse effect in the 39-year-old female.
The patient is experiencing SSRI-induced sexual dysfunction (anorgasmia).
Switching to a non-serotonergic agent like bupropion is standard management for resolving sexual side effects while maintaining antidepressant efficacy.
3
Evaluate the new acute symptoms in the 22-year-old university student.
The patient exhibits classic signs of treatment-emergent mania (agitation, hyper-religiosity, decreased need for sleep).
Antidepressants can unmask bipolar disorder. All offending antidepressants must be stopped immediately to halt the manic episode before adding mood stabilizers.
4
Analyze the treatment response in the 48-year-old female.
The patient has had a partial response to an optimized, maximum dose of an SSRI.
Augmentation strategies (e.g., with an atypical antipsychotic, lithium, or thyroid hormone) are preferred over switching when there is a significant but incomplete response to the current medication.

Key Concept

Pharmacological and Somatic Management of Depressive Disorders and Complications
Question 2Question →

Evaluate the following clinical scenarios detailing distinct neurocognitive or acute neuropsychiatric presentations. Pair each patient vignette with the single most appropriate next step in management or definitive therapeutic intervention.

Click a left item, then click its matching right item

Items

A hospitalized patient experiences severe rigidity, autonomic instability, and worsening confusion shortly after receiving haloperidol for well-formed visual hallucinations. The family reports a pre-existing history of acting out dreams.
An ambulatory patient presents with a newly developed 'glued-to-the-floor' ambulation pattern, concurrent with uninhibited detrusor contractions and mild executive dysfunction. Brain imaging demonstrates enlarged ventricles without proportional cortical atrophy.
A previously tactful executive begins making highly inappropriate comments to colleagues, exhibits profound emotional blunting, and develops a compulsive eating pattern focused exclusively on carbohydrates. Memory testing remains surprisingly intact.
A patient rapidly deteriorates into akinetic mutism and exhibits exaggerated myoclonic jerks upon exposure to loud noises. This catastrophic decline occurred over a period of mere weeks. EEG demonstrates characteristic periodic biphasic sharp waves.
An individual with known major neurocognitive disorder due to Alzheimer disease abruptly exhibits a fluctuating level of consciousness, disorganized thinking, and inattention on the second day following an orthopedic surgery.

Matches

Show answer & explanation

Answer

Match the DLB vignette with antipsychotic discontinuation; NPH with CSF removal; bvFTD with SSRI therapy; CJD with palliative care; and delirium with evaluation for systemic triggers.
Each correct pairing links the pathognomonic clinical presentation of a neurocognitive or acute neuropsychiatric syndrome with its evidence-based standard of care or immediate next management step.

Step-by-Step Solution

1
Analyze the first vignette focusing on haloperidol sensitivity in the context of visual hallucinations and dream enactment.
Diagnosis is Dementia with Lewy Bodies presenting with severe neuroleptic sensitivity.
Patients with DLB lack dopamine and are exquisitely sensitive to dopamine antagonists, requiring immediate cessation of haloperidol.
2
Identify the etiology behind the 'glued-to-the-floor' gait, incontinence, and enlarged ventricles.
Diagnosis is Normal Pressure Hydrocephalus.
The standard diagnostic and initial therapeutic step for NPH is high-volume CSF drainage to document gait improvement before considering permanent shunting.
3
Evaluate the isolated behavioral changes, loss of tact, and hyperorality without initial memory deficits.
Diagnosis is behavioral variant Frontotemporal Dementia.
Management for bvFTD relies heavily on symptom control using SSRIs to blunt impulsivity and compulsive behaviors.
4
Assess the rapidly progressive presentation featuring akinetic mutism, myoclonus, and specific EEG findings.
Diagnosis is Creutzfeldt-Jakob disease.
CJD is uniformly fatal and non-treatable; the focus shifts entirely to palliative care and appropriate prion precautions.
5
Differentiate acute post-surgical cognitive fluctuation from chronic progressive dementia.
Diagnosis is post-operative delirium superimposed on Alzheimer disease.
Delirium is a medical emergency necessitating rapid investigation of underlying causes (e.g., sepsis, medication effects) rather than primary psychiatric interventions.

Key Concept

Targeted management and definitive interventions for major neurocognitive disorders based on underlying pathophysiology.
Question 3Question →

Evaluate the following distinct patient presentations encountered in an outpatient clinic and pair each with its most accurate diagnostic classification based on DSM-5 criteria.

Click a left item, then click its matching right item

Items

A 24-year-old woman consistently declines invitations to social gatherings and avoids the workplace cafeteria due to an intense, persistent fear of embarrassing herself while eating or speaking in front of others.
A 42-year-old woman spends several hours each day silently mentally reviewing her past conversations to ensure she did not accidentally insult anyone, causing significant distress and frequent lateness to work.
A 33-year-old man restricts his travel to a narrow radius around his home and absolutely refuses to use public transportation, fearing he might experience a sudden, incapacitating panic attack with no way to get help or escape.
A 28-year-old woman presents with a history of recurrent, unexpected episodes of palpitations, shortness of breath, and a fear of dying that peak within minutes. She now constantly worries about when the next episode will occur.
A 36-year-old man reports chronic, persistent worry about his health, his family's safety, and minor everyday tasks for the past 9 months, accompanied by poor sleep, irritability, and muscle tension.

Matches

Show answer & explanation

Answer

The presentations match as follows: Presentation 1 (fear of scrutiny) to Social Anxiety Disorder; Presentation 2 (mental reviewing) to Obsessive-Compulsive Disorder; Presentation 3 (fear of no escape) to Agoraphobia; Presentation 4 (unexpected attacks and anticipatory worry) to Panic Disorder; Presentation 5 (chronic pervasive worry for more than 6 months) to Generalized Anxiety Disorder.
Each presentation highlights the defining DSM-5 criteria for specific anxiety and obsessive-compulsive disorders. Social Anxiety Disorder is driven by fear of negative evaluation; Obsessive-Compulsive Disorder features obsessions and compulsions; Agoraphobia involves fear of being unable to escape; Panic Disorder requires recurrent unexpected attacks and anticipatory anxiety; Generalized Anxiety Disorder involves pervasive, difficult-to-control worry for at least 6 months.

Step-by-Step Solution

1
Identify the core fear or primary symptom driving the patient's distress in each presentation.
The core fears are: scrutiny by others (Presentation 1), accidental harm necessitating mental review (Presentation 2), inability to escape if incapacitated (Presentation 3), having another panic attack (Presentation 4), and widespread daily worries (Presentation 5).
Psychiatric diagnoses in this category are primarily differentiated by the underlying motivation for anxiety or avoidance behaviors.
2
Apply DSM-5 duration and criteria thresholds to each identified core symptom.
Presentation 5 meets the 6-month requirement for Generalized Anxiety Disorder. Presentation 4 meets the requirement of unexpected attacks plus 1 month of anticipatory worry for Panic Disorder. The others perfectly match the defining clinical features of Social Anxiety Disorder, Obsessive-Compulsive Disorder, and Agoraphobia, respectively.
Accurate diagnosis requires both the correct symptom profile and adherence to temporal diagnostic criteria.

Key Concept

Differentiating anxiety, obsessive-compulsive, and related disorders based on core clinical features, primary fears, and timeframes.
Question 4Question →

Match each clinical scenario describing an adverse pharmacological event in a patient being treated for bipolar disorder to the most accurate underlying mechanism of the interaction.

Click a left item, then click its matching right item

Items

A 42-year-old man with bipolar I disorder presents to the clinic with severe ataxia, coarse tremors, and confusion. Physical exam shows bilateral horizontal nystagmus. Mental status exam reveals disorientation. He recently started lisinopril and hydrochlorothiazide for hypertension. His serum creatinine is 1.41.4 mg/dL (baseline 0.90.9 mg/dL).
A 24-year-old man with a history of brief, distinct periods of euphoric mood and decreased need for sleep presents to the outpatient clinic with profound sadness and fatigue. He is prescribed paroxetine monotherapy. He returns to the ED two weeks later exhibiting severe agitation, pressured speech, flight of ideas, and grandiosity.
A 31-year-old man with bipolar depression presents to the emergency department with a rapidly spreading, painful maculopapular rash and mucosal ulcerations. A novel mood stabilizer was recently initiated at a standard titration dose while he was concurrently maintained on divalproex sodium.
A 28-year-old woman with rapid-cycling bipolar disorder presents to her obstetrician reporting missed menses. She experiences an unintended pregnancy despite perfect adherence to combined oral contraceptives. A new maintenance psychiatric medication was added two months ago.
A 35-year-old woman treated with a fixed-dose combination of fluoxetine and olanzapine for acute bipolar depression presents to the ED with altered mental status. Temperature is 39.2∘C39.2^\circ C. Physical exam reveals prominent inducible clonus in the lower extremities and diaphoresis. She recently took over-the-counter dextromethorphan.

Matches

Show answer & explanation

Answer

The correct matches pair each clinical presentation with its specific pharmacokinetic or pharmacodynamic drug interaction mechanism, correctly linking thiazides to lithium toxicity, SSRI monotherapy to manic switch, valproate-lamotrigine to glucuronidation inhibition, carbamazepine to CYP450 induction, and fluoxetine-dextromethorphan to serotonin syndrome.
Each clinical scenario corresponds to a classic, high-yield pharmacological complication encountered in bipolar disorder management. Recognizing these specific medication interactions (CYP450 induction, glucuronidation inhibition, renal clearance changes) is critical for safe prescribing.

Step-by-Step Solution

1
Analyze each clinical vignette to identify the underlying adverse effect or complication.
Patient 1 has lithium toxicity; Patient 2 has a manic switch; Patient 3 has Stevens-Johnson syndrome/TEN; Patient 4 has OCP failure; Patient 5 has serotonin syndrome.
Accurate recognition of the clinical toxidrome or event is required before identifying the pharmacological mechanism.
2
Identify the interacting medications in each scenario.
Patient 1: lithium + ACEi/thiazide. Patient 2: SSRI monotherapy in unrecognized bipolar disorder. Patient 3: valproate + lamotrigine. Patient 4: carbamazepine + OCPs. Patient 5: fluoxetine + dextromethorphan.
Drug-drug interactions in psychiatry frequently rely on precise CYP450, UGT, or renal clearance alterations.
3
Map the medication combination to the correct physiological or molecular mechanism.
Matches are finalized based on the established pharmacokinetic and pharmacodynamic profiles of mood stabilizers and antipsychotics.
This confirms the understanding of maintenance therapy management and its pitfalls.

Key Concept

Pharmacokinetic and pharmacodynamic interactions of mood stabilizers and antipsychotics in the management of bipolar disorder.
Question 5Question →

A 48-year-old man is brought to the clinic by his sister due to a 5-month history of progressive forgetfulness, social withdrawal, and difficulty concentrating. The sister reports that he takes an unusually long time to answer simple questions and that his walking has become slow and uncoordinated. His medical history is significant for HIV infection, diagnosed 12 years ago. He admits to poor adherence to his antiretroviral therapy over the past 18 months. His most recent CD4+ T-cell count was 145/mm³. Vital signs are within normal limits. Neurological examination reveals marked psychomotor slowing, saccadic pursuit eye movements, and brisk deep tendon reflexes in the bilateral lower extremities. His Montreal Cognitive Assessment score is 19/30. Magnetic resonance imaging of the brain demonstrates diffuse cortical atrophy and symmetric, bilateral periventricular white matter hyperintensities without contrast enhancement or mass effect. Which of the following is the most likely diagnosis?

Show answer & explanation

Answer: HIV-associated neurocognitive disorder

Answer

The correct diagnosis is HIV-associated neurocognitive disorder.
HIV-associated neurocognitive disorder (HAND) is a neurodegenerative condition resulting from HIV infection of the central nervous system, typically seen in patients with long-standing, poorly controlled disease and low CD4+ counts. It classically presents with a subcortical pattern of dementia characterized by a triad of cognitive impairment (memory loss, executive dysfunction), behavioral changes (apathy, social withdrawal), and motor abnormalities (psychomotor retardation, slow gait, hyperreflexia, saccadic eye movements). Magnetic resonance imaging characteristically demonstrates diffuse cortical atrophy and symmetric periventricular white matter hyperintensities. Importantly, there is no mass effect, edema, or contrast enhancement, which perfectly matches this patient's presentation.

Step-by-Step Solution

1
Identify the core clinical syndrome based on the history and physical exam.
The patient exhibits a triad of cognitive decline (forgetfulness, MoCA 19/30), behavioral changes (apathy, social withdrawal), and motor symptoms (psychomotor retardation, hyperreflexia).
Establishing the specific pattern of neurological deficits is essential for narrowing the differential diagnosis in an immunocompromised patient.
2
Analyze the neuroimaging findings in the context of the patient's immune status.
MRI shows diffuse cortical atrophy and symmetric periventricular white matter hyperintensities, with no mass effect, edema, or contrast enhancement.
Imaging differentiates neurodegenerative processes from focal opportunistic infections or malignancies.
3
Synthesize the clinical and imaging data to determine the most likely etiology.
The insidious onset, symmetric subcortical imaging findings, and lack of focal deficits in a poorly controlled HIV patient point directly to a primary viral neurodegenerative process rather than an opportunistic infection.
This confirms HIV-associated neurocognitive disorder and rules out conditions like PML or toxoplasmosis.

Key Concept

HIV-associated neurocognitive disorder (HAND) typically presents with subcortical cognitive decline, behavioral apathy, and motor symptoms (hyperreflexia, psychomotor slowing). MRI classically shows diffuse atrophy and symmetric white matter changes without enhancement or mass effect.
Estimated Time:1m 15s
Question 6Question →

A 32-year-old man presents to the outpatient clinic with a 2-month history of persistent sadness, profound fatigue, early morning awakening, and difficulty concentrating at work. He reports that his symptoms have led to a recent poor performance review. He denies suicidal ideation, psychotic symptoms, or active medical problems. Physical examination and baseline laboratory studies are unremarkable. You suspect major depressive disorder (MDD) and plan to initiate treatment. Arrange the following clinical management steps in the most appropriate chronological sequence, assuming the patient eventually requires treatment escalation due to an initial inadequate response.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first screen for bipolar disorder, then initiate an SSRI, follow up in 4-6 weeks to assess efficacy, and finally augment or switch if the initial trial is unsuccessful.
The standard sequence for managing a new presentation of major depressive disorder begins with diagnostic safety—specifically, screening for a history of mania or hypomania to rule out bipolar disorder and avoid antidepressant-induced manic switching. Once unipolar depression is confirmed, a first-line agent (such as an SSRI) is initiated. Because these medications take time to alter receptor sensitivity and promote neurogenesis, a 4 to 6 week trial is necessary to accurately assess clinical efficacy. Only after this trial period is completed and deemed inadequate should the physician escalate therapy by augmenting the current medication or switching to an alternative agent.

Step-by-Step Solution

1
Identify the primary prerequisite diagnostic safety check before starting antidepressants.
Screening for manic/hypomanic episodes is identified as the first mandatory step.
Antidepressants can trigger mania in patients with undiagnosed bipolar disorder.
2
Determine the initial pharmacological treatment intervention.
Initiating an SSRI monotherapy follows the screening.
SSRIs are standard first-line treatments for unipolar major depressive disorder.
3
Establish the correct timeframe for evaluating the initial treatment.
Reassessing in 4 to 6 weeks is the subsequent step.
This duration constitutes an adequate trial to observe the full therapeutic benefits of the medication.
4
Decide on the appropriate management strategy for a failed initial treatment trial.
Augmenting or switching the antidepressant is the final step in this clinical sequence.
Treatment escalation is indicated only after an adequate initial trial fails to produce remission.

Key Concept

The foundational stepped-care management of Major Depressive Disorder requires ruling out bipolar disorder prior to initiating a first-line antidepressant, followed by an adequate trial period of 4 to 6 weeks before considering augmentation or switching strategies.
Estimated Time:1m 0s
Question 7Question →

A 61-year-old retired engineer is brought to the physician by his daughter for a psychiatric evaluation. Over the past five weeks, he has become increasingly withdrawn, spending most of the day in bed. He reports waking up at 3:00 AM daily and being unable to return to sleep. His daughter notes he has lost approximately 5.5 kg (12 lb) during this period and no longer shows interest in his usual hobbies, such as gardening. Two weeks ago, the patient's primary care provider diagnosed him with a major depressive episode and prescribed fluoxetine. The patient states he feels no better and wants to discontinue the medication. Upon further questioning, the daughter recalls that when her father was in his late thirties, he was briefly given a different antidepressant for sadness. Within days of starting that medication, he became excessively talkative, slept only two hours a night for a week, and impulsively bought three luxury vehicles, leading to a brief psychiatric hospitalization. Medical history is otherwise unremarkable, and he takes no other medications. Vital signs are within normal limits. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Discontinue fluoxetine and initiate quetiapine

Answer

Discontinue fluoxetine and initiate quetiapine
This patient is currently experiencing a severe depressive episode, characterized by melancholic features such as terminal insomnia (waking at 3:00 AM), anhedonia, and weight loss. Crucially, his history reveals an episode of severely elevated mood, decreased need for sleep, impulsivity, and hospitalization that occurred after antidepressant exposure. This presentation meets the criteria for a manic episode (antidepressant-induced mania is considered indicative of underlying Bipolar I disorder if the manic symptoms persist beyond the physiological effect of the drug, or in classical definitions, dictates a bipolar spectrum approach). For patients with bipolar depression, standard antidepressant monotherapy (like fluoxetine) is contraindicated as it carries a high risk of inducing a manic switch or rapid cycling. The appropriate next step is to immediately discontinue the fluoxetine and initiate a medication approved for bipolar depression, such as quetiapine, lurasidone, or lithium.

Step-by-Step Solution

1
Analyze the current clinical presentation.
The patient exhibits a major depressive episode with melancholic features (terminal insomnia, significant weight loss, profound anhedonia).
Establishing the current affective state is required for guiding immediate pharmacotherapy.
2
Evaluate the patient's psychiatric history.
The patient had a previous episode of decreased need for sleep, hyper-verbal speech, and impulsivity requiring hospitalization shortly after starting an antidepressant.
A history of mania or hypomania fundamentally changes the diagnosis from Major Depressive Disorder (unipolar) to Bipolar Disorder.
3
Determine the appropriate pharmacologic management based on the revised diagnosis.
The diagnosis is Bipolar I disorder, currently in a depressive episode. The current treatment (fluoxetine monotherapy) is contraindicated.
Antidepressant monotherapy can trigger manic episodes in bipolar patients. The SSRI must be stopped, and a medication efficacious for bipolar depression (e.g., quetiapine, lurasidone, or lithium) should be initiated.

Key Concept

Patients presenting with a depressive episode must be rigorously screened for a history of mania or hypomania prior to initiating, or continuing, antidepressant therapy. Antidepressant monotherapy is contraindicated in Bipolar Disorder due to the risk of inducing mania.
Estimated Time:1m 30s
Question 8Question →

A 2727-year-old man with a history of schizophrenia is brought to the emergency department by his family because he has been standing completely still in the corner of his room for the past 1212 hours. He does not respond to questions, maintains his arm in a raised position when the physician moves it there, and has not eaten or drank anything all day. His current medications include haloperidol and benztropine. Vital signs are temperature 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure 120/80 mm Hg120/80\text{ mm Hg}, pulse 82/min82/\text{min}, and respirations 14/min14/\text{min}. Arrange the following management steps in the most appropriate chronological order for this patient's current condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing catatonia is to first discontinue the offending antipsychotic, perform a lorazepam challenge, initiate scheduled benzodiazepines, and reserve ECT for refractory cases.
The patient is presenting with catatonia, characterized by immobility, mutism, waxy flexibility (maintaining a posture set by the examiner), and refusal to eat or drink. The management of catatonia follows a specific algorithm. The first step is to discontinue any potentially exacerbating medications, particularly dopamine antagonists (antipsychotics) like haloperidol, which can worsen the condition or trigger neuroleptic malignant syndrome. Once the offending agent is removed, the initial therapeutic and diagnostic step is the lorazepam challenge test (11-2 mg2\text{ mg} IV), which usually results in marked, rapid, but temporary improvement. Upon a positive challenge, the patient is transitioned to scheduled, standing doses of lorazepam to maintain remission. Electroconvulsive therapy (ECT) is considered the definitive treatment but is generally reserved for patients who fail to respond to a full trial of high-dose benzodiazepines, or for those presenting with malignant catatonia (catatonia accompanied by autonomic instability, fever, and rigidity).

Step-by-Step Solution

1
Identify the clinical syndrome.
The patient's mutism, immobility, waxy flexibility, and negativism are diagnostic of catatonia.
Accurate diagnosis is required to guide the specific algorithm for psychiatric intervention.
2
Determine the first step in management.
Discontinue haloperidol.
Dopamine-blocking agents (like haloperidol) can exacerbate catatonia and increase the risk of progression to neuroleptic malignant syndrome (NMS). They must be stopped immediately.
3
Select the initial pharmacological intervention.
Administer an intravenous lorazepam challenge.
Lorazepam 11 to 2 mg2\text{ mg} IV is used to confirm the diagnosis and typically provides rapid, temporary relief of catatonic symptoms.
4
Determine the maintenance strategy.
Initiate scheduled, continuous benzodiazepine therapy.
Because the lorazepam challenge only provides temporary relief, scheduled high-dose benzodiazepines are required to sustain improvement.
5
Identify the definitive treatment for refractory cases.
Prepare the patient for electroconvulsive therapy (ECT).
If the patient does not respond to benzodiazepines within several days, or if the catatonia becomes malignant (with fever and autonomic instability), ECT is the treatment of choice.

Key Concept

Algorithm for the Management of Catatonia
Question 9Question →

During a routine psychiatric intake at a community mental health center, an architect presents voluntarily, seeking help for what he describes as "constant emotional whiplash." The patient reports a long-standing history of intense, tumultuous romantic involvements that invariably end abruptly. He struggles with chronic feelings of inner emptiness and admits to frequent episodes of binge drinking and reckless driving whenever he perceives his partner is withdrawing. Last week, following his therapist's announcement of an upcoming vacation, the patient superficially lacerated his own thighs. Throughout today's interview, his demeanor shifts dramatically; he initially praises the evaluating physician as a "brilliant lifesaver," but later becomes overtly hostile, shouting that the physician is "just as dismissive and useless as the rest of them" after being asked to clarify a timeline. The patient has never experienced distinct manic episodes. He notes occasional feelings of being "detached from reality" during extreme stress, which rapidly resolve once the stressor passes.

Which of the following statements regarding the diagnosis and optimal evidence-based management of this patient's condition are correct? (Select exactly 2 answers)

Select all that apply

Show answer & explanation

Answer: The treatment team must establish firm, unified limits and engage in frequent interdisciplinary communication to counteract the effects of the patient's primary defense mechanism.; The psychosocial intervention with the strongest evidence base for this condition prioritizes the development of mindfulness, distress tolerance, and emotional regulation skills.

Answer

The correct approaches involve establishing unified team boundaries to manage splitting and utilizing Dialectical Behavior Therapy (DBT) to teach emotional regulation and distress tolerance.
The patient displays classic features of Borderline Personality Disorder (BPD): intense fear of abandonment, chronic emptiness, impulsivity, non-suicidal self-injury, and transient stress-related dissociation. The sudden shift from idealization to devaluation demonstrates the defense mechanism of splitting. Effective management requires the treatment team to maintain strict, unified boundaries to prevent manipulation and staff division. Furthermore, Dialectical Behavior Therapy (DBT), which focuses on mindfulness, interpersonal effectiveness, emotional regulation, and distress tolerance, is the gold-standard psychosocial intervention for BPD.

Step-by-Step Solution

1
Identify the primary psychiatric diagnosis based on the clinical presentation.
The patient's fear of abandonment, chronic emptiness, impulsivity, non-suicidal self-injury, intense anger, and transient stress-related dissociation confirm Borderline Personality Disorder (BPD).
Accurate diagnosis is required to select appropriate psychotherapy and anticipate interpersonal dynamics during treatment.
2
Evaluate the patient's interaction style with the evaluating physician.
The abrupt shift from praising the physician as a 'brilliant lifesaver' to shouting that they are 'dismissive and useless' is a classic demonstration of splitting.
Recognizing this defense mechanism dictates the behavioral management strategy for the clinical team.
3
Select the most appropriate evidence-based interventions for BPD.
The primary interventions are Dialectical Behavior Therapy (DBT) and ensuring a unified team approach with consistent limits.
DBT directly targets emotional dysregulation, while consistent team boundaries prevent the patient from successfully polarizing the healthcare providers.

Key Concept

Diagnosis and management of Borderline Personality Disorder (BPD), targeting the defense mechanism of splitting and emphasizing Dialectical Behavior Therapy.
Question 10Question →

Match each patient's clinical presentation with the most appropriate next step in pharmacological or procedural management.

Click a left item, then click its matching right item

Items

A 72-year-old man with a 6-week history of severe depressed mood, a 15-lb (6.8-kg) weight loss, and the steadfast conviction that his intestines are rotting as a punishment for past sins. He is currently refusing all food and fluids.
A 55-year-old man with a 4-month history of pervasive sadness, anhedonia, and poor concentration, accompanied by a 2-year history of bilateral, symmetrical burning pain in his lower extremities due to poorly controlled diabetes mellitus.
A 28-year-old woman presenting with severe depression and psychomotor retardation. Chart review reveals a past emergency department visit three years prior for a two-week period of decreased need for sleep, pressured speech, and reckless spending.
A 45-year-old woman with major depressive disorder who reports a partial (50%) improvement in symptoms after 8 weeks of escitalopram at the maximum tolerated dose. She continues to struggle with residual fatigue but denies suicidal ideation.

Matches

Show answer & explanation

Answer

The 72-year-old man with psychotic depression and food refusal matches with Electroconvulsive therapy. The 55-year-old man with depression and diabetic neuropathy matches with Duloxetine monotherapy. The 28-year-old woman with a history of mania matches with Quetiapine monotherapy. The 45-year-old woman with a partial response to escitalopram matches with Aripiprazole augmentation.
Each patient represents a specific clinical scenario requiring tailored psychiatric management. The elderly patient in a life-threatening state due to psychotic depression requires ECT. The patient with comorbid painful neuropathy benefits from duloxetine's dual SNRI action. The young woman with past mania requires an atypical antipsychotic approved for bipolar depression (quetiapine). The patient with a robust but incomplete response to an SSRI requires augmentation (aripiprazole).

Step-by-Step Solution

1
Analyze the 72-year-old man's presentation.
Identified major depressive disorder with psychotic features (delusions of rotting intestines) and life-threatening oral intake refusal.
This establishes an indication for urgent, definitive treatment rather than waiting weeks for pharmacotherapy to take effect.
2
Analyze the 55-year-old man's presentation.
Identified major depressive disorder with comorbid neuropathic pain (diabetic peripheral neuropathy).
Guides the selection of a dual-action antidepressant (SNRI) that addresses both mood and neuropathic pain pathways.
3
Analyze the 28-year-old woman's presentation.
Identified a current depressive episode in a patient with a clear history of a manic episode (decreased sleep, pressured speech, impulsivity).
Changes the diagnosis from unipolar major depressive disorder to bipolar I disorder, fundamentally altering the pharmacological approach.
4
Analyze the 45-year-old woman's presentation.
Identified treatment-resistant depression defined by a partial response to an adequate 8-week trial of an SSRI at maximum dose.
Determines that augmenting the current regimen to capitalize on the partial response is superior to cross-titrating to a new monotherapy.

Key Concept

Tailoring management of depressive disorders based on clinical specifiers (e.g., psychotic features), comorbidities, treatment history, and bipolar risk.
Question 11Question →

A patient with a recent history of ischemic heart disease is evaluated at an outpatient psychiatry practice. The 5858-year-old male suffered a myocardial infarction 33 months prior, for which he takes aspirin, ticagrelor, rosuvastatin, and metoprolol. He now describes a 66-week history of unremitting dysphoria, anhedonia, insomnia, and feelings of worthlessness, without any thoughts of self-harm. His physical examination and vital signs are unremarkable at this visit. A diagnosis of major depressive disorder is established, and pharmacotherapy is initiated. Eight days following this appointment, the patient arrives at the urgent care clinic complaining of severe dizziness and near-fainting episodes. Triage vital signs demonstrate a pulse of 40/min40\text{/min} and a blood pressure of 88/54 mm Hg88/54\text{ mm Hg}. A 1212-lead electrocardiogram confirms pronounced sinus bradycardia. Which of the following psychiatric medications is most likely responsible for precipitating this patient's acute presentation?

Show answer & explanation

Answer: Paroxetine

Answer

Paroxetine
The correct answer is the medication that acts as a potent CYP2D6 inhibitor. The patient's presentation of new-onset severe bradycardia and hypotension shortly after starting psychiatric therapy strongly suggests metoprolol toxicity. Metoprolol is extensively metabolized in the liver by the cytochrome P450 2D6 (CYP2D6) enzyme. Paroxetine (along with fluoxetine) is a potent inhibitor of CYP2D6. Co-administration of paroxetine blocks the clearance of metoprolol, leading to elevated beta-blocker concentrations and resulting in symptomatic bradycardia and cardiogenic presyncope.

Step-by-Step Solution

1
Identify the primary acute clinical syndrome.
The patient presents with severe sinus bradycardia and hypotension 8 days after starting a new medication.
This establishes that the patient is suffering from an acute adverse drug effect.
2
Analyze the patient's existing medication regimen for potential interactions.
The patient is taking metoprolol, a beta-blocker known to cause bradycardia and hypotension when serum levels are excessively high.
This links the acute symptoms to a potential toxicity of an existing medication rather than a direct effect of a new one.
3
Determine the metabolic pathway of metoprolol and evaluate the new medication choices.
Metoprolol is metabolized by CYP2D6. Among the choices, paroxetine is a potent CYP2D6 inhibitor, which would lead to decreased metoprolol clearance and subsequent toxicity.
Identifying the pharmacokinetic interaction correctly isolates the most likely causative agent.

Key Concept

Pharmacokinetic drug-drug interactions: Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) can severely decrease the metabolism of beta-blockers like metoprolol, precipitating dangerous bradycardia and hypotension.
Question 12Question →

A psychiatric clinical pharmacist is reviewing the pharmacotherapy regimens of six patients being treated for various phases of bipolar disorder. Each scenario involves a critical drug-drug interaction, a specific administration requirement, or a major prescribing pitfall. Match each clinical scenario with the precise pharmacokinetic or pharmacodynamic rationale that governs its clinical management.

Click a left item, then click its matching right item

Items

A patient stabilized on lithium carbonate is prescribed hydrochlorothiazide for newly diagnosed essential hypertension.
A patient maintained on divalproex sodium is initiated on lamotrigine to manage a breakthrough episode of bipolar depression.
A patient with rapid-cycling bipolar disorder treated with carbamazepine requests a prescription for a combined oral contraceptive pill.
A patient administered sublingual asenapine for acute mania is instructed to strictly avoid eating or drinking for 10 minutes post-dose.
A patient prescribed ziprasidone for bipolar maintenance therapy is heavily counseled to take the medication exclusively alongside a 500-calorie meal.
A patient with bipolar I disorder presenting with a major depressive episode is inappropriately prescribed paroxetine monotherapy by an outside provider.

Matches

Show answer & explanation

Answer

Lithium + HCTZ pairs with compensatory proximal tubular reabsorption; Valproate + Lamotrigine pairs with UGT inhibition; Carbamazepine + OCP pairs with CYP3A4 induction; Asenapine pairs with extensive first-pass metabolism; Ziprasidone pairs with dietary fat dependence; Paroxetine monotherapy pairs with the risk of treatment-emergent affective switch.
Bipolar disorder management requires meticulous attention to pharmacokinetic and pharmacodynamic interactions. Lithium is renally cleared and highly sensitive to volume shifts caused by thiazides, which paradoxically increase its proximal reabsorption. Valproate inhibits UGT, necessitating a slower lamotrigine titration to avoid Stevens-Johnson syndrome. Carbamazepine is a potent CYP3A4 auto-inducer that diminishes the efficacy of OCPs. Specific atypical antipsychotics have unique absorption profiles: asenapine requires transmucosal absorption to bypass first-pass metabolism, while ziprasidone requires dietary fat to be absorbed. Finally, SSRI monotherapy (paroxetine) is a major pharmacodynamic pitfall due to the risk of inducing acute mania.

Step-by-Step Solution

1
Evaluate the lithium and hydrochlorothiazide combination.
Matches with compensatory enhancement of proximal tubular reabsorption.
Thiazides inhibit the Na+/Cl- cotransporter in the distal tubule. The resulting volume depletion leads to increased proximal reabsorption of sodium and lithium, precipitating lithium toxicity.
2
Evaluate the divalproex sodium and lamotrigine combination.
Matches with inhibition of UDP-glucuronosyltransferase (UGT).
Valproate inhibits the glucuronidation of lamotrigine, dramatically increasing lamotrigine levels and the risk of life-threatening rashes like Stevens-Johnson syndrome.
3
Evaluate the carbamazepine and oral contraceptive pill combination.
Matches with induction of cytochrome P450 3A4 (CYP3A4).
Carbamazepine upregulates hepatic CYP3A4, which increases the clearance of oral contraceptives, causing therapeutic failure (unintended pregnancy).
4
Evaluate the sublingual asenapine administration instructions.
Matches with extensive hepatic first-pass metabolism.
If patients drink or eat immediately after sublingual asenapine, the drug is washed into the stomach and undergoes heavy first-pass metabolism, rendering it ineffective.
5
Evaluate the ziprasidone administration instructions.
Matches with adequate gastrointestinal absorption depending on dietary fat.
Ziprasidone's absorption is highly food-dependent; it must be taken with a substantial (>500 calorie) meal to achieve adequate therapeutic serum levels.
6
Evaluate the paroxetine monotherapy scenario in bipolar I disorder.
Matches with unopposed monoaminergic reuptake inhibition causing an affective switch.
SSRIs given without a mood stabilizer in bipolar I patients can precipitate a severe manic episode.

Key Concept

Pharmacokinetics, pharmacodynamics, and critical drug-drug interactions of mood stabilizers and atypical antipsychotics in Bipolar Disorder.
Estimated Time:2m 30s
Question 13Question →

A 74-year-old retired teacher is brought to her primary care physician by her daughter due to progressive forgetfulness and difficulty managing her finances over the past two years. Her medical history includes well-controlled hypertension and hyperlipidemia. The physician suspects a major neurocognitive disorder. Arrange the following diagnostic steps in the most appropriate sequential clinical workflow, from the initial encounter to advanced diagnostic testing.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequential workflow is: 1) Clinical interview and medication review, 2) Objective bedside cognitive screening, 3) Laboratory testing for reversible causes, 4) Structural neuroimaging, and 5) Formal neuropsychological testing.
The evaluation of suspected major neurocognitive disorder follows a logical progression from least invasive and most fundamental to most specialized. It begins with a comprehensive history and medication review, as collateral information is vital and polypharmacy is a frequent culprit. This is immediately followed by a bedside cognitive screen (e.g., MoCA) to objectively quantify the deficit. Once impairment is confirmed, standard laboratory tests are drawn to rule out reversible metabolic or nutritional causes. Structural imaging follows to exclude macroscopic brain pathology such as tumors, bleeds, or hydrocephalus. Finally, if the diagnosis remains uncertain, formal neuropsychological testing is requested to clarify the specific neurocognitive domains affected.

Step-by-Step Solution

1
Initiate the evaluation with a comprehensive history and medication review.
Establishes the timeline of symptoms, incorporates caregiver collateral information, and rules out polypharmacy.
History is the most critical component of psychiatric and neurologic diagnoses.
2
Administer an objective screening tool like the MoCA or MMSE.
Provides quantifiable evidence of cognitive impairment.
Subjective memory complaints must be objectively verified before proceeding with an extensive medical workup.
3
Check routine blood tests (e.g., Vitamin B12, TSH).
Identifies or excludes common systemic, endocrine, or nutritional causes of pseudodementia or reversible cognitive decline.
Ruling out reversible medical conditions is a mandatory next step in the dementia algorithm.
4
Order structural neuroimaging (MRI or CT).
Visualizes the brain parenchyma to check for infarcts, masses, hydrocephalus, or distinct regional atrophy.
Imaging helps differentiate between neurodegenerative causes (like Alzheimer's) and structural/vascular causes.
5
Consider formal neuropsychological testing.
Yields a detailed profile of cognitive strengths and weaknesses across multiple domains.
This is a specialized, final diagnostic step used when standard evaluation fails to confidently differentiate between dementia subtypes or distinguish dementia from major depressive disorder.

Key Concept

Standard diagnostic evaluation pathway for major neurocognitive disorders.
Question 14Question →

A 31-year-old woman with severe, treatment-resistant atypical depression has failed multiple antidepressant trials. She is currently taking fluoxetine 60 mg daily but remains profoundly symptomatic. Her psychiatrist decides to transition her to phenelzine.

Arrange the following clinical steps in the correct chronological sequence to safely and effectively execute this medication transition and its long-term management.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with discontinuing fluoxetine, followed by a mandatory 5-week washout period. After the washout, phenelzine is initiated alongside a tyramine-restricted diet, followed by dose titration with orthostatic blood pressure monitoring. Finally, if phenelzine fails, a 2-week washout is required before starting a new serotonergic agent.
The correct sequence respects the unique pharmacokinetics of fluoxetine and the irreversible nature of MAOIs. Fluoxetine must be stopped, followed by a 5-week washout (due to norfluoxetine's long half-life). Phenelzine is then started alongside a low-tyramine diet to prevent hypertensive crisis. During titration, monitoring for orthostatic hypotension (the most common side effect) is critical. Finally, if phenelzine is stopped, a 14-day washout is required before starting a new serotonergic drug to allow for the regeneration of the MAO enzyme.

Step-by-Step Solution

1
Identify the medications involved in the transition.
The transition is from fluoxetine (an SSRI) to phenelzine (an MAOI).
Understanding the specific drugs dictates the pharmacokinetic rules required to prevent fatal drug interactions like Serotonin Syndrome.
2
Determine the required washout period for discontinuing fluoxetine.
A 5-week washout period is identified as mandatory.
Fluoxetine has a unique pharmacokinetic profile with a very long-acting metabolite (norfluoxetine), necessitating 5 weeks rather than the standard 2 weeks required for other antidepressants.
3
Establish the protocol for initiating the MAOI.
Phenelzine is started concurrently with a tyramine-restricted diet, followed by titration and blood pressure monitoring.
MAOIs inhibit the breakdown of tyramine, which can cause a hypertensive crisis if ingested. Furthermore, orthostatic hypotension is the most common dose-dependent side effect.
4
Establish the protocol for discontinuing the MAOI if it fails.
A 14-day (2-week) washout is required after stopping phenelzine.
Because phenelzine irreversibly inhibits MAO, it takes approximately 14 days for the body to synthesize a new supply of the enzyme before a serotonergic agent can be safely reintroduced.

Key Concept

Pharmacological transition protocols and washout periods between SSRIs and MAOIs.
Question 15Question →

Match each clinical presentation describing a medication-induced psychiatric emergency or toxidrome with its most appropriate definitive pharmacological treatment.

Click a left item, then click its matching right item

Items

A 45-year-old man develops severe 'lead-pipe' muscle rigidity, a temperature of 104°F (40°C), and altered mental status a week after starting fluphenazine.
A 28-year-old woman presents with ocular clonus, hyperreflexia, tremor, and agitation shortly after taking linezolid while on chronic sertraline therapy.
A 72-year-old man exhibits hot and dry skin, dilated pupils, tachycardia, urinary retention, and visual hallucinations after an intentional amitriptyline overdose.
A 22-year-old man presents to the emergency department with a sustained upward deviation of his eyes and a twisted neck hours after receiving an injection of haloperidol.

Matches

Show answer & explanation

Answer

Fluphenazine-induced NMS matches with Bromocriptine; Sertraline/linezolid-induced Serotonin Syndrome matches with Cyproheptadine; Amitriptyline-induced Anticholinergic Toxicity matches with Physostigmine; Haloperidol-induced Acute Dystonia matches with Benztropine.
Each psychiatric emergency requires a specific pharmacological intervention that targets the underlying receptor pathophysiology. NMS is caused by dopamine blockade and is treated with bromocriptine (dopamine agonist). Serotonin syndrome is caused by excess serotonin and is treated with cyproheptadine (serotonin antagonist). Anticholinergic toxicity is treated with physostigmine (increasing acetylcholine). Acute dystonia is caused by a relative excess of acetylcholine following dopamine blockade and is treated with benztropine (anticholinergic).

Step-by-Step Solution

1
Analyze the first presentation (fluphenazine) to identify the toxidrome.
Identified as Neuroleptic Malignant Syndrome (NMS) due to lead-pipe rigidity and hyperthermia.
Recognizing the classic tetrad of NMS (fever, rigidity, mental status changes, autonomic instability) is essential for selecting a dopamine agonist.
2
Evaluate the second presentation (sertraline + linezolid).
Identified as Serotonin Syndrome due to hyperreflexia and clonus after combining serotonergic drugs.
Differentiating Serotonin Syndrome from NMS by the presence of hyperreflexia dictates the use of a serotonin antagonist.
3
Examine the third presentation (amitriptyline).
Identified as Anticholinergic Toxicity based on the classic toxidrome of dry skin, mydriasis, and delirium.
TCAs have strong anticholinergic properties; diagnosing this correctly leads to the use of a cholinesterase inhibitor.
4
Assess the final presentation (haloperidol).
Identified as Acute Dystonia (oculogyric crisis, torticollis).
Acute extrapyramidal symptoms occurring hours after typical antipsychotic administration require anticholinergic reversal.

Key Concept

Pharmacological management of acute psychiatric medication-induced emergencies and toxidromes.
Question 16Question →

A 19-year-old college sophomore is evaluated at the university counseling center for a 6-month history of severe anxiety. She reports experiencing frequent, distressing images of herself being covered in deadly bacteria. To relieve this distress, she spends up to 4 hours a day washing her hands and disinfecting her belongings, causing her to fail two classes this semester. Three weeks ago, she visited a community clinic for low mood and was prescribed phenelzine, which she has been taking daily. She is now seeking treatment specifically for her intrusive thoughts and repetitive behaviors. Which of the following are appropriate management steps? (Select 2)

Select all that apply

Show answer & explanation

Answer: Initiate exposure and response prevention therapy; Discontinue phenelzine and observe a 14-day washout period before starting sertraline

Answer

The most appropriate next steps are to initiate exposure and response prevention (ERP) therapy and to discontinue phenelzine, observe a 14-day washout period, and then start an SSRI such as sertraline.
The patient's presentation of distressing, intrusive thoughts accompanied by time-consuming neutralizing behaviors confirms a diagnosis of Obsessive-Compulsive Disorder (OCD). First-line treatments for OCD include exposure and response prevention (ERP) therapy and Selective Serotonin Reuptake Inhibitors (SSRIs). ERP can be initiated immediately as it carries no pharmacologic interaction risk. However, because the patient is currently taking phenelzine (a monoamine oxidase inhibitor), an SSRI cannot be started immediately. A mandatory 14-day washout period is required after discontinuing the MAOI to allow for the regeneration of the MAO enzyme; failure to wait risks precipitating life-threatening serotonin syndrome.

Step-by-Step Solution

1
Identify the primary psychiatric diagnosis.
The patient is diagnosed with Obsessive-Compulsive Disorder (OCD).
She presents with persistent, distressing obsessions (images of bacteria) and time-consuming compulsions (handwashing for 4 hours a day).
2
Determine the standard first-line therapies for OCD.
First-line treatments include exposure and response prevention (ERP) therapy and Selective Serotonin Reuptake Inhibitors (SSRIs).
These modalities have the strongest evidence base for reducing OCD symptoms.
3
Evaluate the patient's current medication for potential drug interactions.
The patient is currently taking phenelzine, an MAOI. A 14-day washout period is required before starting an SSRI.
Combining an MAOI with an SSRI, or starting an SSRI too soon after stopping an MAOI, risks precipitating life-threatening serotonin syndrome.

Key Concept

Management of OCD involves ERP therapy and SSRIs, but initiating serotonergic agents in a patient on an MAOI requires a 14-day washout period to prevent serotonin syndrome.
Question 17Question →

Match the following patient clinical profiles with the most appropriate next step in management.

Click a left item, then click its matching right item

Items

70-year-old man, 3 weeks post-myocardial infarction, meeting criteria for major depressive disorder.
28-year-old woman in her first trimester of pregnancy with psychotic depression and refusal of oral intake.
40-year-old man with major depressive disorder, experiencing persistent sexual dysfunction and fatigue on an SSRI.
25-year-old woman with major depressive disorder characterized by prominent insomnia and significant weight loss.
22-year-old man with severe depression and a history of a 7-day period of euphoric mood, grandiosity, and decreased need for sleep.

Matches

Show answer & explanation

Answer

The most appropriate management strategies are matched as follows: the post-myocardial infarction patient with sertraline, the pregnant patient with psychotic depression with urgent electroconvulsive therapy, the patient with SSRI-induced sexual dysfunction with bupropion augmentation, the patient with insomnia and weight loss with mirtazapine, and the patient with a history of mania with quetiapine.
The correct matches align specific interventions with the unique clinical presentations of each patient, ensuring efficacy while minimizing risks and addressing prominent side effects or symptoms.

Step-by-Step Solution

1
Assess the cardiovascular risk profile of the 70-year-old man.
Identify that a post-myocardial infarction status requires a medication with high cardiac safety.
Tricyclic antidepressants and some SSRIs can cause arrhythmias or interact with cardiac medications; sertraline is proven safe.
2
Evaluate the acuity of the 28-year-old pregnant woman.
Determine that psychosis and food refusal necessitate a rapid, life-saving intervention.
Electroconvulsive therapy is highly effective and safe for both the mother and fetus in psychiatric emergencies.
3
Analyze the side effect burden of the 40-year-old man.
Recognize that SSRI-induced sexual dysfunction and residual fatigue require a mechanism change.
Adding an NDRI like bupropion targets these specific residual symptoms without compounding sexual dysfunction.
4
Identify the prominent neurovegetative symptoms in the 25-year-old woman.
Select an agent that promotes sleep and appetite.
Mirtazapine's antagonism of H1 receptors directly treats her insomnia and weight loss.
5
Recognize the past manic episode in the 22-year-old man's history.
Diagnose bipolar I depression and select an appropriate mood-stabilizing agent.
Quetiapine treats bipolar depression while avoiding the risk of a manic switch associated with SSRI monotherapy.

Key Concept

Tailoring the pharmacological and procedural management of depressive disorders requires careful consideration of medical comorbidities, prominent symptom profiles, clinical acuity, and past psychiatric history.
Estimated Time:1m 30s
Question 18Question →

Diagnostic boundaries in psychiatry often hinge on precise symptom duration and the exact nature of the triggering event. For each of the following patient encounters, determine the single most appropriate DSM-5 diagnosis by differentiating between overlapping clinical features.

Click a left item, then click its matching right item

Items

A 22-year-old man avoids attending university lectures and eating in the cafeteria due to intense palpitations and sweating. He is terrified that others will notice his hands shaking and judge him as weak. He is completely comfortable in densely crowded places, such as large music festivals, as long as he remains anonymous.
A 45-year-old woman presents with severe muscle tension, fatigue, and insomnia. For the past 7 months, she has been unable to control her excessive worry concerning her husband's health, her work performance, and minor home maintenance. Her husband had a mild myocardial infarction 8 months ago, but her anxiety has since generalized to unrelated domains.
A 30-year-old paramedic responded to a catastrophic multi-vehicle collision 25 days ago. He reports experiencing intrusive visual memories of the scene, marked physiological reactivity when hearing sirens, and an inability to experience positive emotions. He now takes a longer route to work to avoid the highway.
A 29-year-old woman was unexpectedly terminated from her corporate job 4 months ago. She experiences recurrent, distressing thoughts about the day she was fired, avoids driving past her former office building, feels socially detached, and has severe insomnia. She frequently states her life is permanently ruined.
A 38-year-old woman has spent the past year avoiding flying on airplanes, traveling on subways, and visiting enclosed shopping malls. She has never had a full panic attack, but she is terrified of suddenly developing incapacitating, panic-like symptoms (such as dizziness or loss of bowel control) and being unable to escape or obtain help.

Matches

Show answer & explanation

Answer

The clinical vignettes demonstrate subtle diagnostic boundaries. The correct matches are: the student avoiding lectures has Social Anxiety Disorder; the woman with multi-domain worry has Generalized Anxiety Disorder; the paramedic at 25 days post-trauma has Acute Stress Disorder; the fired corporate worker has Adjustment Disorder; and the woman avoiding travel has Agoraphobia.
Each diagnosis is established by strictly applying DSM-5 exclusionary criteria. Social Anxiety Disorder involves fear of scrutiny. GAD requires more than 6 months of multi-domain worry. Acute Stress Disorder is restricted to trauma symptoms lasting less than 1 month. Adjustment Disorder applies to significant distress from non-Criterion A stressors. Agoraphobia involves fear of entrapment without necessitating recurrent unexpected panic attacks.

Step-by-Step Solution

1
Identify the core underlying fear in each vignette.
Fear of social scrutiny indicates Social Anxiety Disorder, while fear of being trapped with incapacitating symptoms indicates Agoraphobia.
Differentiating anxiety disorders requires isolating the primary cognitive distortion driving the avoidance behavior.
2
Determine if the precipitating stressor meets DSM-5 Criterion A for trauma.
Job loss does not involve actual or threatened death, serious injury, or sexual violence, defaulting the diagnosis to Adjustment Disorder despite the severity of the reaction.
PTSD and Acute Stress Disorder cannot be diagnosed without a qualifying Criterion A trauma.
3
Evaluate the exact timeline of the presenting symptoms.
Trauma-related symptoms lasting less than 1 month (25 days) indicate Acute Stress Disorder, while generalized worry spanning multiple domains for more than 6 months confirms Generalized Anxiety Disorder.
Psychiatric diagnoses frequently change based entirely on duration thresholds.

Key Concept

Accurate psychiatric diagnosis requires strict adherence to DSM-5 criteria regarding the precise duration of symptoms, the specific definition of a Criterion A trauma, and the patient's core underlying fear.
Question 19Question →

A 75-year-old man is brought to the clinic by his daughter for a cognitive evaluation. Over the past 5 months, he has stopped managing his finances, spends most of the day sitting in a recliner, and frequently complains that his memory is 'completely gone.' When the physician asks him to perform serial sevens and recall three objects, he sighs loudly, states 'I just cannot do this anymore,' and refuses to try. Five months ago, he was forced to surrender his driver's license due to worsening macular degeneration. His daughter notes that he has lost 4.5 kg (10 lb) during this period. Neurologic examination is nonfocal. Which of the following is the most likely diagnosis?

Show answer & explanation

Answer: Major depressive disorder

Answer

Major depressive disorder
This patient is presenting with cognitive impairment secondary to major depressive disorder, a clinical picture often referred to as 'pseudodementia.' In the elderly, depression frequently manifests with prominent memory complaints. Key features that differentiate pseudodementia from genuine major neurocognitive disorder (like Alzheimer disease) include a more rapid onset (often following a stressor, such as losing driving privileges), intense distress or complaints about memory loss, and a characteristic lack of effort on cognitive testing. Instead of attempting to answer and making mistakes, depressed patients typically sigh, give up easily, or answer 'I do not know.' Furthermore, the patient's pervasive inactivity and significant weight loss are classic neurovegetative symptoms that confirm a major depressive episode.

Step-by-Step Solution

1
Identify the psychosocial stressor and timeline.
The patient lost his driver's license 5 months ago, correlating with the subacute onset of his symptoms.
A clear precipitating event with a subacute onset of cognitive complaints strongly suggests a psychiatric etiology rather than an insidious neurodegenerative disease.
2
Evaluate the patient's attitude toward his cognitive deficits.
He complains that his memory is 'completely gone' and refuses to try during the cognitive assessment.
Patients with depression-related cognitive impairment (pseudodementia) typically emphasize their deficits and show poor effort, unlike patients with genuine dementia who often lack insight and attempt to cover up their mistakes.
3
Look for neurovegetative symptoms of depression.
The patient exhibits severe anhedonia (sitting in a recliner all day) and a 10-lb weight loss.
These somatic symptoms confirm the presence of a major depressive episode.

Key Concept

Major depressive disorder in the elderly can present with prominent cognitive complaints (pseudodementia). It is differentiated from genuine major neurocognitive disorder by a subacute onset, exaggerated complaints about memory loss, poor effort on cognitive testing, and concurrent vegetative symptoms of depression.
Question 20Question →

A 25-year-old primigravida at 14 weeks gestation is evaluated in the emergency department for sudden-onset palpitations, chest tightness, trembling, and a feeling of impending doom that awoke her from sleep. The episode peaked within 10 minutes and has now resolved. She has had three similar unexpected episodes over the past month. She now refuses to leave her house unless accompanied by her husband, fearing she will have an attack in public. Medical history is notable for a hospitalization at age 19 for a manic episode with psychotic features; she had been stable on lithium but discontinued it 6 months prior to conception.

Her temperature is 37.0°C (98.6°F), blood pressure is 112/70 mm Hg, pulse is 92/min, and respirations are 18/min. Pulse oximetry is 99% on room air. She mentions a chronic, mild sensation of breathlessness over the last few weeks. Physical examination is unremarkable.

Laboratory results:
- TSH: 0.2 μ\mu IU/mL (normal: 0.4-4.0 μ\mu IU/mL)
- Free T 4_4: 1.3 ng/dL (normal: 0.8-1.8 ng/dL)

Arterial blood gas analysis on room air:
- pH: 7.45
- PaCO 2_2: 30 mm Hg
- PaO 2_2: 102 mm Hg

The patient's husband is distressed by her avoidance behaviors and demands she be given an intravenous sedative immediately. However, the patient explicitly declines any pharmacotherapy due to fear of teratogenicity. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate cognitive-behavioral therapy

Answer

The most appropriate next step in management is to initiate cognitive-behavioral therapy.
Initiating cognitive-behavioral therapy is the most appropriate next step. The patient's clinical presentation of recurrent, unexpected episodes of intense fear accompanied by physical symptoms and subsequent avoidance behavior confirms a diagnosis of panic disorder with agoraphobia. Because she has a history of bipolar I disorder (which precludes standard SSRI monotherapy) and explicitly refuses pharmacotherapy due to her pregnancy, cognitive-behavioral therapy is the safest and most effective first-line, evidence-based intervention.

Step-by-Step Solution

1
Diagnose the patient's primary psychiatric condition based on the clinical presentation.
The patient has recurrent, unexpected episodes of intense fear with physical symptoms and subsequent avoidance behavior, confirming a diagnosis of Panic Disorder with Agoraphobia.
Accurate diagnosis is required before selecting a treatment modality.
2
Evaluate the patient's comorbidities and their impact on standard treatment options.
The patient has a history of Bipolar I Disorder. This contraindicates the use of SSRI or SNRI monotherapy, which are standard pharmacological treatments for panic disorder, due to the high risk of precipitating a manic switch.
Pharmacological interventions must be safe given the patient's full psychiatric history.
3
Assess the objective laboratory and physiological data to rule out medical mimics.
The mild dyspnea, isolated slightly low TSH, and compensated respiratory alkalosis are all normal physiologic changes of pregnancy. No urgent medical intervention is required for these findings.
It is crucial to differentiate between pathological states (e.g., hyperthyroidism, pulmonary embolism) and normal pregnancy physiology to avoid unnecessary interventions.
4
Incorporate the patient's preferences and ethical principles into the management plan.
The patient is competent and explicitly refuses pharmacotherapy. Her autonomy must be respected, pointing clearly to an evidence-based non-pharmacological treatment.
Patient autonomy allows competent patients to refuse any treatment, guiding the provider toward the best acceptable alternative.

Key Concept

Cognitive-behavioral therapy is the safest and most appropriate first-line treatment for panic disorder in a pregnant patient who has a history of bipolar disorder and who refuses pharmacotherapy.
Estimated Time:1m 30s
Page 1 / 41Next